CAJ | 학술논문

目的探讨不同剂量重组人促红细胞生成素(recombinant human erythropoietin,rHu-EPO)对心肌梗死大鼠血流动力学和左室梗死面积的影响.方法选取成年SD大鼠64只,随机分为假手术组、心肌梗死对照组、大剂量治疗组和小剂量治疗组.各组分别于术后24 h和2周检测血流动力学指标和左室梗死面积.结果术后24 h:与假手术组相比,心肌梗死对照组LVSP、LVEDP和±dp/dt_(max)显著恶化;与心肌梗死对照组相比,大、小剂量治疗组±dp/dt_(max)有显著改善.术后2周:与假手术组相比,心肌梗死对照组LVSP、LVEDP和±dp/dt_(max)显著恶化;与心肌梗死对照组相比,大、小剂量治疗组±dp/dt_(max)有显著改善,梗死面积显著缩小;与大剂量治疗组相比,小剂量治疗组±dp/dt_(max)有显著改善.结论心肌梗死后即刻给予大剂量rHu-EPO,并术后减量维持治疗1周可明显缩小梗死面积,保护心功能,小剂量维持治疗的改善心功能效果更好.
목적 탐토불동제량중조인촉홍세포생성소(recombinant human erythropoietin,rHu-EPO)대심기경사대서혈류동역학화좌실경사면적적영향.방법 선취성년SD대서64지,수궤분위가수술조、심기경사대조조、대제량치료조화소제량치료조.각조분별우술후24 h화2주검측혈류동역학지표화좌실경사면적.결과 술후24 h:여가수술조상비,심기경사대조조LVSP、LVEDP화±dp/dt_(max)현저악화;여심기경사대조조상비,대、소제량치료조±dp/dt_(max)유현저개선.술후2주:여가수술조상비,심기경사대조조LVSP、LVEDP화±dp/dt_(max)현저악화;여심기경사대조조상비,대、소제량치료조±dp/dt_(max)유현저개선,경사면적현저축소;여대제량치료조상비,소제량치료조±dp/dt_(max)유현저개선.결론 심기경사후즉각급여대제량rHu-EPO,병술후감량유지치료1주가명현축소경사면적,보호심공능,소제량유지치료적개선심공능효과경호.
Objective To investigate the effect of recombinant human erythropoietin (rHu-EPO) in different doses on hemodynamic status and infarct size of left ventricle in rats with myocardial infarction. Methods Adult SD rats were divided randomly into 4 groups: sham group (Sham), myocardial infarction group(MI), treatment group with high dose (MITH), treatment group with low dose (MITL). Hemodynamic parameters and infarct size were tested 24 hours and 2 weeks after operation for all groups. Results 24 hours after operation, LVSP, LVEDP and ±dp/dt_(max) in MI group were significantly worse than those in Sham group, while ±dp/dt_(max) in the two treatment groups were remarkably better than those in MI group. 2 weeks after operation, MI group showed significantly worse LVSP,LVEDP and ±dp/dt_(max) than Sham group, while compared with MI group the two treatment group demonstrated remarkably improved ±dp/dt_(max) and significantly decreased infarct size (P<0.05). ±dp/dt_(max) in MITL group were remarkably better than those in MITH group. Conclusion High dose of rHu-EPO immediately after myocardial infarction and maintenance treatment with low dose for one week can significantly reduce infarct size and protect cardiac function. For maintenance treatment, rHu-EPO in low dose leads to better cardiac function than high dose.